Chicago-based 32 Biosciences, a precision gut microbiome medicine company, has secured $6 million in funding to accelerate development of its diagnostic platform and therapeutic pipeline.
Led by CEO Peter Farmakis, the company leverages AI/machine learning to assess the functional health of the gut microbiome—aiming to diagnose, prevent, and treat chronic diseases by restoring microbiome balance.